Developing therapies for rare diseases has long been a financial and scientific challenge for the pharmaceutical industry. With small patient populations, high research costs, and complex regulatory pathways, companies often struggle to create viable business models. Yet, the need remains urgent—over 90% of rare diseases still lack an FDA-approved treatment. Fortunately, innovative...